TMO Thermo Fisher Scientific Inc
$609.82▲ +1.10%
Healthcare
Other
After hours
$609.82▲ +0.00%
Sep 11, 6:06 PM ET
Volume 1.78M
Avg Volume (10D) 1.65M
Key Metrics & Fundamentals
Market Cap
$225.48B
P/E Ratio
32.8
Div Yield
0.31%
52W Range
435.27 - 647.00
% vs 50 MA
5.42%
% vs 200 MA
13.64%
RSI-14
54.8
MACD Histogram
-4.4300
Beta (1Y vs SPY)
0.60
Free Cash Flow
$1.68B
Gross Rev
$11.99B
Gross Profit
$4.88B
EBITDA
$3.24B
COGS
$7.11B
Operating Exp
$2.70B
Operating Income
$2.19B
EBIT
$2.19B
Pretax Income
$1.92B
Net Income
$1.74B
EPS (Diluted)
4.68
Price & Volume History
Loading chart…
Recent News
Advanced Bioreactor Systems Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)
GlobeNewswire · Sep 11, 2026 8:09 AM
Transcriptome Sequencing Market - Global Forecast to 2035; Bulk RNA-Seq Maintains Its Technology Market Lead
GlobeNewswire · Sep 10, 2026 11:03 AM
Organoid Intelligence Market - Global Forecast to 2036; Biological Computing and Brain Organoids Drive Growth
GlobeNewswire · Sep 10, 2026 11:02 AM
Thermo Fisher, Danaher Could Log Mid-Single-Digit Organic Revenue Growth in 2027, UBS Says
MT Newswires · Sep 9, 2026 5:55 PM
Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls
The Fly · Sep 9, 2026 1:51 PM
UBS Upgrades Thermo Fisher Scientific to Buy From Neutral, Adjusts Price Target to $730 From $540
MT Newswires · Sep 9, 2026 1:20 PM
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Abercrombie & Fitch, Affirm Holdings, Eagle Materials, Klarna Group, Martin Marietta Materials, Oklo, Qualcomm, Robinhood Markets, Ulta Beauty, and More
24/7 Wall St. · Sep 9, 2026 12:06 PM
ILMN Stock Keeps Climbing. Should You Climb On?
Trefis · Sep 8, 2026 7:37 PM
My Green Lab Expands ACT Ecolabel Channel Partner Network Ahead of New EU Environmental Claims Rules
GlobeNewswire · Sep 8, 2026 5:51 PM
Blood Based Biomarkers Market Report Now Available — See Why the First FDA-Cleared Alzheimer's Blood Test Just Redrew the Competitive Map
GlobeNewswire · Sep 8, 2026 3:52 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See TMO's money flow as a full page
Social Sentiment
Avg +0.38 · 16 posts
NewsDiscussionTradeWith most 13Fs released, here are superinvestors' top 10 buys from Q2
r/stocks · Aug 15, 2026
Listed as a significant investment by superinvestors.
positive
+0.60
NewsDDTMO impending fraud scandal
r/wallstreetbets · Jun 8, 2026
The post frames a potential fraud scandal involving TMO, expressing significant concern.
negative
-0.80
NewsDiscussionDDNew U.S. Government Investment Targets - Thermo Fisher?
r/wallstreetbets · Oct 15, 2025
The author’s assessment of TMO’s role suggests a positive view of the company’s potential impact.
positive
+0.80
Morningstar: "10 Best Value Stocks"
r/stocks · Jul 22, 2025
The post includes a direct positive comment referencing TMO as a 'good long term hold' amidst a list of value stocks.
positive
+0.60
TradeDiscussiondid we just turn value?
r/wallstreetbets · Jul 1, 2025
TMO is listed as one of the core holdings of the author.
positive
+0.70
Page 1 of 4 (16 total)
AI Analysis
Generated May 20, 3:23 AM
Company Overview
Thermo Fisher Scientific is a global leader in scientific instrumentation, reagents, consumables, and software services, serving a diverse range of customers across healthcare, life sciences, diagnostics, and industrial markets. Its broad portfolio and integrated solutions provide a strong competitive moat, making it an essential partner in scientific research and development worldwide.
Bull Case
- Highly diversified product and service portfolio across critical life science, diagnostic, and applied markets, providing revenue stability and resilience.
- Essential nature of its products and services ensures consistent demand from pharmaceutical, biotech, academic, and government clients for ongoing research and development.
- Strong track record of innovation and significant R&D investment, positioning the company to capitalize on emerging scientific trends and maintain technological leadership.
- Strategic acquisitions have consistently expanded market reach, product offerings, and technological capabilities, reinforcing its dominant market position.
Bear Case
- Exposure to economic downturns and funding fluctuations in research and development budgets, which could impact demand for its instruments and consumables.
- Intense competition from other large, well-established players and specialized firms, potentially leading to pricing pressures and market share erosion.
- Regulatory risks in highly regulated sectors like healthcare and diagnostics, where changes in policies, approvals, or reimbursement could affect product viability.
- Significant international operations expose the company to adverse currency fluctuations, which can impact reported revenues and profitability.
Recent Performance
TMO has experienced a significant downturn, currently trading 30.5% below its 52-week high and showing a strong bearish trend as it sits 8.5% below its 50-day moving average and 16.1% below its 200-day moving average. Despite a modest +1.3% daily gain, the RSI-14 of 35.4 indicates persistent selling pressure and weak momentum, with the stock trading closer to its 52-week low, signaling a substantial correction.
AI-generated analysis is for informational purposes only and does not constitute financial advice.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.